Oragenics to Showcase Promising Concussion Treatment in Upcoming Webinar
TL;DR
Oragenics (NYSE American: OGEN) is hosting a management update webinar discussing its lead candidate for concussion treatment, providing early access advantage for investors.
Oragenics focuses on nasal delivery of pharmaceutical medications in neurology. The lead candidate, ONP-002, in Phase IIa trial targets mild traumatic brain injury.
Oragenics' intranasal therapy for concussion treatment aims to reduce brain inflammation and swelling, offering hope for improved care and outcomes in traumatic brain injuries.
Oragenics' webinar presents a breakthrough in concussion treatment with promising preclinical results, highlighting the potential of ONP-002 in addressing brain injuries.
Found this article helpful?
Share it with your network and spread the knowledge!
Oragenics Inc., a development-stage biotechnology company, will host a management update webinar on May 20, 2025, to discuss its promising drug candidate ONP-002 for treating mild traumatic brain injury (mTBI), commonly known as concussion.
The webinar will feature key company leadership, including CEO Janet Huffman, Chief Medical Officer Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a national emergency medicine expert. They will address the critical unmet medical need in concussion treatment and provide insights into the company's lead intranasal therapy.
ONP-002 is currently undergoing a Phase IIa clinical trial and has demonstrated significant potential in preclinical studies. Preliminary research suggests the drug can effectively reduce brain inflammation and swelling associated with mild traumatic brain injury, offering hope for improved treatment options.
The presentation represents an important opportunity for investors, medical professionals, and researchers to gain deeper understanding of potential therapeutic innovations in neurology. By focusing on intranasal delivery, Oragenics is exploring a novel approach to addressing complex neurological conditions that currently have limited treatment options.
The webinar will provide a comprehensive overview of the company's ongoing research and development efforts in developing targeted neurological therapies, potentially signaling a significant advancement in concussion treatment strategies.
Curated from InvestorBrandNetwork (IBN)
